thioinosine has been researched along with Abnormalities--Drug-Induced* in 4 studies
4 other study(ies) available for thioinosine and Abnormalities--Drug-Induced
Article | Year |
---|---|
Combined prenatal toxicity of 6-mercaptopurine riboside and hydroxyurea in mice.
Hydroxyurea (HU) and 6-mercaptopurine riboside (6-MPr) are used as cytostatic chemotherapeutics. Their teratogenic potential in experimental animals has been well known for several decades. Generally, it is assumed that the toxicity of both agents is due to an interference with enzymes of DNA synthesis. In the case of 6-MPr, it was speculated that the teratogenicity in rodents might be paralleled by or even correlated to an incorporation of 6-thioguanine into the DNA of the embryos. In this study, the interaction between these two compounds with regard to teratogenicity in NMRI mice was investigated. Dose-response data of 6-MPr (s.c.-treatment) were published earlier. First, a dose-response study with HU alone (i.p.-treatment) was performed. From these data, the doses for the combination study were derived: HU 250 mg/kg (NOAEL dose) and 6-MPr 16 mg/kg (strongly teratogenic dose). In all experimental groups the substances were administered to the dams once on day 11 of gestation. Combination effects were investigated applying various dosing regimens. In group I treatment was simultaneous, in group II HU was administered 2 h before 6-MPr, in group III 2 h after 6-MPr. The differences in the overall frequency of gross structural abnormalities were moderate. However, when analysing the effects in more detail (single abnormalities), group III exhibited great differences: 1) 6-MPr co-treatment increased the frequency of HU effects (skull defects) and 2) HU co-treatment decreased the frequency of 6-MPr effects (limb defects) when compared to the findings of the dose-response studies. In addition, the influence of HU on the 6-MPr-induced DNA modification was determined by measuring the incorporation of 6-thioguanine into the DNA of day-11 embryos. As expected, the HU co-treatment corresponding to the group III dosing regimen of the teratogenicity experiment decreased the incorporation rate by ca. 40%. This was in parallel to the decrease in the frequency of 6-MPr effects in the teratogenicity III group. This finding may be considered as a further indication that in the case of 6-MPr, DNA modification is accompanying teratogenicity. Topics: Abnormalities, Drug-Induced; Animals; DNA; Dose-Response Relationship, Drug; Female; Hydroxyurea; Limb Deformities, Congenital; Maternal-Fetal Exchange; Mice; Pregnancy; Skull; Teratogens; Thioguanine; Thioinosine | 1999 |
Dose-response relationship of teratogenicity and prenatal-toxic risk estimation of 6-mercaptopurine riboside in mice.
6-Mercaptopurine riboside (6-MPr) is used as a cytostatic chemotherapeutic. The teratogenic potential in rodents has been well known for several decades. In this study, the teratogenic risk of low doses of 6-MPr in NMRI mice was estimated based on a dose-response study. The effective doses corresponding to the incidences of 5%, 1%, and 0.1% were calculated using the probit and Weibull model. The evaluation was performed on the basis of both the fetus and the litter by evaluating the variable all gross structural abnormalities. From these experiments, benchmark doses were obtained which were used in low-dose risk assessment to define a reference dose. Depending on the biometrical model and the statistical unit used, values between 1.9 and 5.2 mg/kg (benchmark ED1) and 3.8 and 6.7 mg/kg (benchmark ED5) were obtained. These values were compared to the no observed adverse effect level (NOAEL) which was determined experimentally. The NOAEL was found to be 5 mg/kg, which is quite similar to the ED5 benchmark doses. Topics: Abnormalities, Drug-Induced; Animals; Antimetabolites, Antineoplastic; Cleft Palate; Dose-Response Relationship, Drug; Embryonic and Fetal Development; Female; Fetus; Foot Deformities, Congenital; Maternal-Fetal Exchange; Mice; Pregnancy; Risk Assessment; Teratogens; Thioinosine | 1996 |
Ectodermal and mesodermal cell death patterns in 6-mercaptopurine riboside-induced digital deformities.
Topics: Abnormalities, Drug-Induced; Animals; Cell Survival; Ectoderm; Female; Injections, Intravenous; Inosine; Mesoderm; Pregnancy; Rats; Thioinosine; Toes | 1980 |
Interference of 6-mercaptopurine riboside, 6-methylmercaptopurine riboside and azathioprine with the morphogenetic differentiation of mouse extremities in vivo and in organ culture.
Topics: Abnormalities, Drug-Induced; Animals; Azathioprine; Depression, Chemical; Drug Interactions; Extremities; Female; Gestational Age; Inosine; Mice; Mice, Inbred C57BL; Organ Culture Techniques; Pregnancy; Thioinosine; Time Factors | 1977 |